The U.S. Dupixent market, valued at USD 11.04 billion in 2024, is anticipated to grow at a CAGR of 5.7% from 2025 to 2034, driven by robust performance across multiple therapeutic segments and evolving patient demand patterns. As a monoclonal antibody targeting the interleukin-4 receptor alpha subunit, Dupixent has demonstrated superior efficacy in treating type 2 inflammation-driven diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The segmentation-driven growth of the market is underpinned by product differentiation, application-specific growth, and value chain optimization init